arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2024 Gilead Sciences, Inc. All rights reserved. IHQ-UNB-5423 March 2024

GU/GI/GYN research.

UC is the most common type of bladder cancer and occurs when the urothelial cells that line the bladder and other parts of the urinary tract grow unusually or uncontrollably. An estimated 82,000 Americans were diagnosed with bladder cancer in 2023, and almost 90% of those diagnoses will be UC.1

Research commitment
Clinical trials in progress
Scientific focus

Committed to patients living with GU/GI/GYN cancer

Select a trial below to view additional details (trial brochure or clinicaltrials.gov)
Timeline is based on trial start dates.
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

2018
TROPHY U-01 (multicohort)a

1L/2L+ mUC

2019
TROPiCS-03b

3L mEC cohort

 
ARC-8c

1-2L mPDAC

2021
TROPiCS-04b

2L+ mUC

2022
ARC-9b,c

2L+ mCRC-

 
ELEVATE Lung & UC

3L+ mUC cohort

2023
ARC-21/EDGE-Gastricc

1-2L upper GI

 
ELEVATE CRC

2L mCRC

 
STAR-221c

1L upper GI

00

Clinical trials in progress

GU/GI/GYN clinical trials actively recruiting.

Rollover trial for links to trial brochures and/or clinicaltrials.gov records.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

1L/2L+ mUC
Phase 2, multi-cohort, open-label study of sacituzumab govitecan in patients with unresectable locally advanced/metastatic urothelial cancer
UC

TROPHY U-01 (multicohort)

2L mCRC
Phase 2, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with bevacizumab and FOLFIRI versus bevacizumab and FOLFIRI in previously treated advanced inoperable mCRC
CRC

ELEVATE CRC

1L upper GI
Phase 3 randomized, open-label, multicenter study of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with previously untreated locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma
UPPER GI

STAR-221a

Scientific focus

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

MoAs in research

sacituzumab govitecan-hziy
dom and zim
etruma and quemli

Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.

aTROPHY U-01 (multicohort): Cohort 2 is evaluating 2L+ patients, Cohort 3 is evaluating 2L patients, and Cohorts 4-6 are evaluating 1L patients. bTrial status: active, not recruiting. cIn collaboration with Arcus Biosciences.

FOLFIRI, FOLinic acid-Fluorouracil-IRInotecan regimen; GEJ, gastroesophageal junction; mCRC, metastatic colorectal cancer; mCRPC, metastatic castrate resistant prostate cancer; mUC, metastatic urothelial cancer; NCT, national clinical trial.

1. National Cancer Institute. Cancer stat facts: Bladder Cancer. Accessed October 16, 2023. Available at: https://seer.cancer.gov/statfacts/html/urinb.html